Skip to content
TrackPodcasts
scienceOct 29, 202245:09pending

TWiV 949: Clinical update with Dr. Daniel Griffin

About this episode

In his weekly clinical update Dr. Griffin discusses progress toward poliomyelitis eradication in Pakistan, polio by the numbers , influenza and COVID-19 vaccination coverage among health care personnel, phase 1/2a safety and immunogenicity of an adenovirus 26 vector RSV vaccine encoding prefusion F in adults 18–50 years and RSV seropositive children 12–24 months, receipt of first and second doses of JYNNEOS vaccine for prevention of Monkeypox, distinguishing SARS-CoV-2 persistence and reinfection, Novavax NVX-COV2373 triggers potent neutralization of Omicron sub-lineages, association between regular physical activity and the protective effect of vaccination against SARS-CoV-2 in a South African case, COVID-19 outcomes in solid organ transplant recipients who received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab treatment, Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralizing antibodies, and Tocilizumab versus Baricitinib in hospitalized patients with severe COVID-19.

Subscribe (free): Apple PodcastsGoogle PodcastsRSSemail

Become a patron of TWiV!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]

Get every episode summarized

Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.

Email me new episodes

Free for 3 shows. No card needed.

No transcript yet

This episode has not been transcribed. Request it and it moves to the front of the queue.

TWiV 949: Clinical update with Dr. Daniel Griffin

This Week in Virology

0:00
45:09

More episodes

More from This Week in Virology

View all episodes →